Consensus $6.59. Sees FY24 revenue up 10%-12%, consensus $222.66B. Sees FY24 adjusted free cash flow $2B. Sees FY24 capital expenditures $500M. Sees FY24 tax rate 23%-25%. The company said, “The company raised its fiscal year 2024 outlook for non-GAAP earnings per share by $0.05 to $6.50 to $6.75 from the preliminary outlook previously communicated at the company’s Investor Day5, which primarily reflects increased expectations for Pharmaceutical segment profit. The company reiterated its fiscal year 2024 Pharmaceutical segment profit outlook for 4% to 6% growth on higher ending fiscal year 2023 Pharmaceutical segment profit. The company also increased its fiscal year 2024 Pharmaceutical revenue outlook, driven by continued growth of GLP-1 medications, which do not meaningfully contribute to segment profit. Additionally, the company narrowed its range for diluted weighted average shares outstanding.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CAH:
- Cardinal Health (NYSE:CAH) Stock Down Despite Positive Q4 Results
- Cardinal Health Reports Fourth Quarter and Full Year Results for Fiscal Year 2023 at High End of Investor Day Guidance
- Cardinal Health reports Q4 EPS $1.55, consensus $1.49
- Notable companies reporting before tomorrow’s open
- CAH Upcoming Earnings Report: What to Expect?